$GOVX

GeoVax Labs (Nasdaq: GOVX) said it completed manufacturing, regulatory, clinical and preclinical milestones for its GEO-MVA pivotal Phase 3 immune-bridging study, scheduled to start in Q4 2026. The company expects a 500-participant trial and to report results in mid-2027, comparing GEO-MVA immune responses with licensed MVA-BN (Imvanex).

GeoVax Labs (GOVX) reported Q2 2026 net loss of $4.43M, or $0.97 per share, and cash of about $3.1M at June 30, 2026. Revenue was $0 after termination of a prior BARDA contract. The company said it is preparing to start a pivotal GEO-MVA immunobridging study in Q4 2026 and advancing its Gedeptin program.

GeoVax Labs (GOVX) reported a year-over-year narrower net loss, citing lower R&D and G&A expenses after BARDA funding ended and a shift toward lead vaccine and oncology programs. The company said its cash runway extends into September 2026, but it warned that funding and ongoing viability remain uncertain without new capital.

GeoVax Labs (GOVX) reported Q2 2026 progress on its lead vaccine and immuno-oncology programs. The company said it narrowed focus after discontinuing its COVID-19 vaccine development. It reported a year-over-year narrower net loss and said its cash position stayed stable as it prepares for a key clinical trial, according to its SEC 8-K.

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_993355.htm EXHIBIT 99.1 ex_993355.htm Exhibit 99.1 GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update Company Advances GEO-MVA Toward Planned Pivotal Immunobridging Study Under Expedited Regulatory Pathway ATLANTA, GA, July 27, 2026 – G

GeoVax Labs (Nasdaq: GOVX) said its GEO-MVA vaccine platform aligns with the U.S. HHS/ASPR PHEMCE multiyear budget for FY2025-2029. The report projects about $66.9B in medical countermeasure needs and expects ~65% to go to threat-agnostic, multi-threat technologies, including domestic manufacturing and stockpile modernization.

GeoVax Labs (Nasdaq: GOVX) said a U.S. procurement of additional ACAM2000 smallpox vaccine supports continued orthopox preparedness and validates long-term investment in vaccine manufacturing and diversified countermeasures. GeoVax linked the environment to its GEO-MVA MVA vaccine program, targeting a Phase 3 start in Q4 2026 and mid-2027 immunobridging data.

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. govx20260617_8k.htm false 0000832489 0000832489 2026-06-17 2026-06-17 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17

GeoVax Labs, Inc. announced a warrant inducement transaction with institutional investors. These investors will exercise existing warrants for approximately $595,000 in gross proceeds and, in return, receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at $1.65 per share. The new warrants will become exercisable after shareholder approval and expire five years later.

GeoVax Labs, Inc. has entered into a warrant inducement agreement with existing institutional investors. This agreement involves the immediate exercise of existing warrants for approximately $595,000, with the company providing new unregistered warrants to purchase up to 1,002,288 shares of common stock. The net proceeds will be used for working capital and general corporate purposes, with the transaction expected to close around May 8, 2026.